US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lexeo Therapeutics

4.88

-0.1800-3.56%

Post-market: 4.80-0.0800-1.64%19:30 EDT

Volume:509.59K

Turnover:2.55M

Market Cap:400.39M

PE:-4.26

High:5.20

Open:5.12

Low:4.84

Close:5.06

52wk High:10.99

52wk Low:3.99

Shares:82.05M

Float Shares:51.24M

Volume Ratio:0.59

T/O Rate:0.99%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.1457

EPS(LYR):-1.8634

ROE:-46.76%

ROA:-27.59%

PB:1.70

PE(LYR):-2.62

Loading ...

Overview Company News Filings

Lexeo Therapeutics Releases Corporate Presentation Outlining Cardiac Gene Therapy Pipeline, AAVrh.10 Platform

Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate

Benzinga Earnings

Lexeo Net Loss Narrows to $25.9 Million in Q2 FY26; R&D Expenses Rise to $19 Million

Press Release: Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics, - Lx2020 Holds Rmat, Orphan Drug, and Fast Track Designations from FDA

THOMSON REUTERS

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Lx2020 for the Treatment of Pkp2 Arrhythmogenic Cardiomyopathy

THOMSON REUTERS

Have Insiders Sold Lexeo Therapeutics Shares Recently?

Simply Wall St.

Top Brass at Lexeo Therapeutics Quietly Unload a Chunk of Company Stock

Lexeo Therapeutics Holds Virtual Annual Stockholder Meeting

Lexeo Therapeutics is Maintained at Overweight by JP Morgan

Lexeo Therapeutics price target lowered to $9 from $12 at JPMorgan

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex

Lexeo Therapeutics Finalizes Study Design for Friedreich Ataxia Gene Therapy

MT Newswires Live

Lexeo finalizes SUNRISE-FA 2 pivotal trial protocol, statistical analysis plan

Lexeo Therapeutics releases corporate presentation on cardiac gene therapy platform for inherited heart disease

Lexeo finalizes SUNRISE-FA 2 pivotal trial design for LX2006 in Friedreich ataxia cardiomyopathy

Lexeo Therapeutics - Topline Data Readout Expected in H2 2027; Bla Submission in H1 2028

THOMSON REUTERS

Lexeo Therapeutics - Sunrise-Fa 2 Initiation on Track for Q2 2026; First Patient Expected by End of June

THOMSON REUTERS

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for Lx2006 Gene Therapy in Friedreich Ataxia

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LXEO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LXEO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","market":"US","secType":"STK","nameCN":"Lexeo Therapeutics","latestPrice":4.88,"timestamp":1787342400000,"preClose":5.06,"halted":0,"volume":509587,"hourTrading":{"tag":"盘后","latestPrice":4.8,"preClose":4.88,"latestTime":"19:30 EDT","volume":10882,"amount":52789.82,"timestamp":1787355006637,"change":-0.08,"changeRate":-0.016393,"amplitude":0.020492},"delay":0,"changeRate":-0.035573122529644216,"floatShares":51240200,"shares":82046255,"eps":-1.145694,"marketStatus":"Market Closed","change":-0.18,"latestTime":"08-21 16:00:00 EDT","open":5.12,"high":5.204,"low":4.84,"amount":2551826.9707125,"amplitude":0.071937,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.145694,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1698984000000,"exchange":"NASDAQ","adjPreClose":5.06,"preHourTrading":{"tag":"盘前","latestPrice":5.06,"preClose":5.06,"latestTime":"08:45 EDT","volume":463,"amount":2331.5497961,"timestamp":1787316356512,"change":0,"changeRate":0,"amplitude":0.197628},"postHourTrading":{"tag":"盘后","latestPrice":4.8,"preClose":4.88,"latestTime":"19:30 EDT","volume":10882,"amount":52789.82,"timestamp":1787355006637,"change":-0.08,"changeRate":-0.016393,"amplitude":0.020492},"volumeRatio":0.5931124111843442,"impliedVol":0.3472,"impliedVolPercentile":0.0478},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","floatShares":51240200,"roa":"-27.59%","roe":"-46.76%","lyrEps":-1.863368,"volumeRatio":0.5931124111843442,"shares":82046255,"dividePrice":0,"high":5.204,"amplitude":0.071937,"preClose":5.06,"low":4.84,"week52Low":3.99,"pbRate":"1.70","week52High":10.99,"institutionHeld":0,"latestPrice":4.88,"eps":-1.145694,"divideRate":0,"volume":509587,"delay":0,"ttmEps":-1.145694,"open":5.12,"prevYearClose":9.93,"prevWeekClose":4.84,"prevMonthClose":4.13,"prevQuarterClose":4.655,"fiveDayClose":4.84,"twentyDayClose":4.66,"sixtyDayClose":5.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LXEO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"LXEO","fiscalQuarterEnding":"2026/06","expectedEps":-0.3,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"pre","actualEps":-0.3},{"market":"US","date":"2026-05-11","symbol":"LXEO","fiscalQuarterEnding":"2026/03","expectedEps":-0.29,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2026-03-30","symbol":"LXEO","fiscalQuarterEnding":"2025/12","expectedEps":-0.32,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-11-05","symbol":"LXEO","fiscalQuarterEnding":"2025/09","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.33},{"market":"US","date":"2025-08-14","symbol":"LXEO","fiscalQuarterEnding":"2025/06","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LXEO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LXEO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":10,"updateTime":1766030400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LXEO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LXEO","date":"2026-08-21","current":-4.259427,"percent":0.39028,"low":-8.903248,"twenty":-6.046619,"median":-4.295552,"eighty":-2.242638,"high":-0.6043,"avg":-4.181489,"sd":1.908285,"marketCap":415134685},"quantilePoints":[{"date":"2023-11-03","current":-4.257819,"twenty":-4.257819,"median":-4.257819,"eighty":-4.257819,"marketCap":271355051},{"date":"2023-11-10","current":-4.199758,"twenty":-4.199758,"median":-4.091377,"eighty":-4.048799,"marketCap":267654754},{"date":"2023-11-17","current":-4.292656,"twenty":-4.257819,"median":-4.118472,"eighty":-4.064282,"marketCap":273575228},{"date":"2023-11-24","current":-4.373941,"twenty":-4.270979,"median":-4.199758,"eighty":-4.070475,"marketCap":278755643},{"date":"2023-12-01","current":-4.923587,"twenty":-4.377038,"median":-4.259754,"eighty":-4.081313,"marketCap":313785113},{"date":"2023-12-08","current":-5.031968,"twenty":-4.945263,"median":-4.26556,"eighty":-4.111505,"marketCap":320692333},{"date":"2023-12-15","current":-4.58828,"twenty":-4.855461,"median":-4.333298,"eighty":-4.161824,"marketCap":306423687},{"date":"2023-12-22","current":-5.849059,"twenty":-5.408075,"median":-4.389424,"eighty":-4.194339,"marketCap":390623587},{"date":"2023-12-29","current":-5.805172,"twenty":-5.505138,"median":-4.537237,"eighty":-4.207282,"marketCap":387692577},{"date":"2024-01-05","current":-5.857039,"twenty":-5.805172,"median":-4.621669,"eighty":-4.218567,"marketCap":391156497},{"date":"2024-01-12","current":-5.896937,"twenty":-5.857039,"median":-4.799136,"eighty":-4.257819,"marketCap":393821051},{"date":"2024-01-19","current":-6.012642,"twenty":-5.955803,"median":-4.957419,"eighty":-4.257819,"marketCap":401548257},{"date":"2024-01-26","current":-6.66298,"twenty":-6.148663,"median":-5.403559,"eighty":-4.260916,"marketCap":444980484},{"date":"2024-02-02","current":-6.706868,"twenty":-6.322251,"median":-5.468033,"eighty":-4.26169,"marketCap":447911493},{"date":"2024-02-09","current":-6.714848,"twenty":-6.590366,"median":-5.777243,"eighty":-4.264786,"marketCap":448444404},{"date":"2024-02-16","current":-6.072489,"twenty":-6.589568,"median":-5.827115,"eighty":-4.287237,"marketCap":405545088},{"date":"2024-02-23","current":-6.343796,"twenty":-6.544084,"median":-5.876988,"eighty":-4.341427,"marketCap":423664054},{"date":"2024-03-01","current":-5.8331,"twenty":-6.543286,"median":-5.916886,"eighty":-4.373941,"marketCap":389557765},{"date":"2024-03-08","current":-5.857039,"twenty":-6.520145,"median":-5.890953,"eighty":-4.383231,"marketCap":391156497},{"date":"2024-03-15","current":-6.292966,"twenty":-6.520145,"median":-5.916886,"eighty":-4.447485,"marketCap":417815207},{"date":"2024-03-22","current":-6.028084,"twenty":-6.505782,"median":-5.977118,"eighty":-4.547445,"marketCap":400228597},{"date":"2024-03-28","current":-6.128418,"twenty":-6.497802,"median":-5.937219,"eighty":-4.601636,"marketCap":406890192},{"date":"2024-04-05","current":-5.265543,"twenty":-6.474661,"median":-5.932845,"eighty":-4.625869,"marketCap":349600479},{"date":"2024-04-12","current":-5.241463,"twenty":-6.410602,"median":-5.90231,"eighty":-4.683238,"marketCap":348001696},{"date":"2024-04-19","current":-4.844139,"twenty":-6.359022,"median":-5.876988,"eighty":-4.791277,"marketCap":321621782},{"date":"2024-04-26","current":-4.88026,"twenty":-6.350977,"median":-5.858281,"eighty":-4.83704,"marketCap":324019956},{"date":"2024-05-03","current":-6.182772,"twenty":-6.32828,"median":-5.876988,"eighty":-4.840714,"marketCap":410498948},{"date":"2024-05-10","current":-6.881509,"twenty":-6.410602,"median":-5.90231,"eighty":-4.84735,"marketCap":477707444},{"date":"2024-05-17","current":-6.653707,"twenty":-6.497802,"median":-5.932845,"eighty":-4.860193,"marketCap":461893680},{"date":"2024-05-24","current":-7.346604,"twenty":-6.546981,"median":-6.018356,"eighty":-4.875444,"marketCap":509993878},{"date":"2024-05-31","current":-7.617118,"twenty":-6.584345,"median":-6.028342,"eighty":-4.885879,"marketCap":528772723},{"date":"2024-06-07","current":-8.28154,"twenty":-6.629029,"median":-6.03658,"eighty":-4.908353,"marketCap":574896200},{"date":"2024-06-14","current":-8.903248,"twenty":-6.66298,"median":-6.072489,"eighty":-4.908353,"marketCap":618054597},{"date":"2024-06-21","current":-7.441521,"twenty":-6.711656,"median":-6.103378,"eighty":-4.917985,"marketCap":516582946},{"date":"2024-06-28","current":-7.05236,"twenty":-6.714848,"median":-6.103378,"eighty":-4.921032,"marketCap":489567767},{"date":"2024-07-05","current":-7.066597,"twenty":-6.782675,"median":-6.120366,"eighty":-4.923587,"marketCap":490556127},{"date":"2024-07-12","current":-8.276794,"twenty":-6.842522,"median":-6.15029,"eighty":-4.991251,"marketCap":574566747},{"date":"2024-07-15","current":-8.352728,"twenty":-6.873712,"median":-6.156275,"eighty":-4.995541,"marketCap":579838001},{"date":"2024-08-02","current":-6.198104,"twenty":-6.865914,"median":-6.161186,"eighty":-4.999831,"marketCap":430266153},{"date":"2024-08-09","current":-5.54792,"twenty":-6.840926,"median":-6.144305,"eighty":-5.014306,"marketCap":385131036},{"date":"2024-08-16","current":-5.180835,"twenty":-6.826318,"median":-6.112265,"eighty":-5.010821,"marketCap":400038148},{"date":"2024-08-23","current":-5.215088,"twenty":-6.797868,"median":-6.103378,"eighty":-5.014306,"marketCap":402683028},{"date":"2024-08-30","current":-4.975314,"twenty":-6.782675,"median":-6.066504,"eighty":-4.996865,"marketCap":384168866},{"date":"2024-09-06","current":-4.881117,"twenty":-6.774695,"median":-6.03259,"eighty":-4.924513,"marketCap":376895445},{"date":"2024-09-13","current":-4.22602,"twenty":-6.738787,"median":-6.028084,"eighty":-4.89684,"marketCap":326312109},{"date":"2024-09-20","current":-4.461512,"twenty":-6.721232,"median":-5.996218,"eighty":-4.873838,"marketCap":344495661},{"date":"2024-09-27","current":-3.814978,"twenty":-6.714848,"median":-5.932845,"eighty":-4.83926,"marketCap":294573545},{"date":"2024-10-04","current":-3.900612,"twenty":-6.71405,"median":-5.90231,"eighty":-4.736975,"marketCap":301185746},{"date":"2024-10-11","current":-3.408218,"twenty":-6.71006,"median":-5.876988,"eighty":-4.623769,"marketCap":263165591},{"date":"2024-10-18","current":-3.89633,"twenty":-6.698313,"median":-5.858281,"eighty":-4.466448,"marketCap":300855136},{"date":"2024-10-25","current":-4.238865,"twenty":-6.663872,"median":-5.849059,"eighty":-4.397847,"marketCap":327303939},{"date":"2024-10-31","current":-3.543091,"twenty":-6.66298,"median":-5.819389,"eighty":-4.373941,"marketCap":273579808},{"date":"2024-11-08","current":-3.378247,"twenty":-6.65417,"median":-5.783228,"eighty":-4.26556,"marketCap":260851321},{"date":"2024-11-15","current":-2.970727,"twenty":-6.653707,"median":-5.678921,"eighty":-4.257819,"marketCap":257253067},{"date":"2024-11-22","current":-2.367417,"twenty":-6.629978,"median":-5.544882,"eighty":-4.208893,"marketCap":205008871},{"date":"2024-11-29","current":-3.142556,"twenty":-6.626181,"median":-5.512207,"eighty":-4.166207,"marketCap":272132743},{"date":"2024-12-06","current":-2.703438,"twenty":-6.607553,"median":-5.450079,"eighty":-4.100138,"marketCap":234106904},{"date":"2024-12-13","current":-2.72253,"twenty":-6.599941,"median":-5.414849,"eighty":-4.066934,"marketCap":235760202},{"date":"2024-12-20","current":-2.306323,"twenty":-6.589568,"median":-5.281597,"eighty":-3.914314,"marketCap":199718319},{"date":"2024-12-27","current":-2.588885,"twenty":-6.578686,"median":-5.241463,"eighty":-3.893837,"marketCap":224187120},{"date":"2025-01-03","current":-2.546883,"twenty":-6.570706,"median":-5.215088,"eighty":-3.826967,"marketCap":220549866},{"date":"2025-01-10","current":-2.604159,"twenty":-6.564766,"median":-5.210806,"eighty":-3.754178,"marketCap":225509758},{"date":"2025-01-17","current":-1.981757,"twenty":-6.550955,"median":-5.17013,"eighty":-3.659982,"marketCap":171612264},{"date":"2025-01-24","current":-2.142882,"twenty":-6.53506,"median":-5.110187,"eighty":-3.528106,"marketCap":185565027},{"date":"2025-01-31","current":-2.005371,"twenty":-6.527327,"median":-5.031968,"eighty":-3.425345,"marketCap":173657111},{"date":"2025-02-07","current":-2.070307,"twenty":-6.515357,"median":-5.011134,"eighty":-3.395373,"marketCap":179280293},{"date":"2025-02-14","current":-1.611936,"twenty":-6.499398,"median":-4.991251,"eighty":-3.192195,"marketCap":139587239},{"date":"2025-02-21","current":-1.539361,"twenty":-6.496206,"median":-4.928215,"eighty":-3.10819,"marketCap":133302506},{"date":"2025-02-28","current":-1.142107,"twenty":-6.453914,"median":-4.914373,"eighty":-2.892068,"marketCap":98901859},{"date":"2025-03-07","current":-1.073351,"twenty":-6.437026,"median":-4.893962,"eighty":-2.779043,"marketCap":92947901},{"date":"2025-03-14","current":-1.134467,"twenty":-6.376035,"median":-4.880688,"eighty":-2.703438,"marketCap":98240308},{"date":"2025-03-21","current":-1.027514,"twenty":-6.356851,"median":-4.852166,"eighty":-2.601104,"marketCap":88978596},{"date":"2025-03-28","current":-1.387527,"twenty":-6.34619,"median":-4.840506,"eighty":-2.545356,"marketCap":136439657},{"date":"2025-04-04","current":-0.891258,"twenty":-6.338037,"median":-4.795483,"eighty":-2.464405,"marketCap":87640072},{"date":"2025-04-11","current":-0.732587,"twenty":-6.311324,"median":-4.74555,"eighty":-2.42393,"marketCap":72037483},{"date":"2025-04-17","current":-0.769723,"twenty":-6.30019,"median":-4.649906,"eighty":-2.355198,"marketCap":75689153},{"date":"2025-04-25","current":-1.238984,"twenty":-6.294572,"median":-4.621669,"eighty":-2.271508,"marketCap":121832978},{"date":"2025-05-02","current":-1.590085,"twenty":-6.292966,"median":-4.546304,"eighty":-2.190247,"marketCap":156357855},{"date":"2025-05-09","current":-1.012793,"twenty":-6.292343,"median":-4.461512,"eighty":-2.110502,"marketCap":99590991},{"date":"2025-05-16","current":-0.81978,"twenty":-6.289736,"median":-4.386933,"eighty":-1.999259,"marketCap":89607702},{"date":"2025-05-23","current":-0.935157,"twenty":-6.278497,"median":-4.373941,"eighty":-1.883139,"marketCap":102219157},{"date":"2025-05-30","current":-0.871396,"twenty":-6.262715,"median":-4.292656,"eighty":-1.737224,"marketCap":95249669},{"date":"2025-06-06","current":-0.992845,"twenty":-6.24372,"median":-4.263625,"eighty":-1.61652,"marketCap":108524884},{"date":"2025-06-13","current":-2.052375,"twenty":-6.232879,"median":-4.257819,"eighty":-1.598825,"marketCap":224338921},{"date":"2025-06-20","current":-2.127645,"twenty":-6.223303,"median":-4.238865,"eighty":-1.614228,"marketCap":232566510},{"date":"2025-06-27","current":-2.06491,"twenty":-6.203846,"median":-4.21373,"eighty":-1.629508,"marketCap":225709077},{"date":"2025-07-03","current":-2.198289,"twenty":-6.20262,"median":-4.195762,"eighty":-1.653954,"marketCap":240288372},{"date":"2025-07-11","current":-2.267449,"twenty":-6.200163,"median":-4.140386,"eighty":-1.70361,"marketCap":247848006},{"date":"2025-07-18","current":-2.104429,"twenty":-6.198104,"median":-4.103992,"eighty":-1.718889,"marketCap":230028868},{"date":"2025-07-25","current":-1.812971,"twenty":-6.182772,"median":-4.083635,"eighty":-1.764727,"marketCap":198170410},{"date":"2025-08-01","current":-2.336608,"twenty":-6.17781,"median":-4.06594,"eighty":-1.812971,"marketCap":255407640},{"date":"2025-08-08","current":-2.198289,"twenty":-6.166096,"median":-4.041907,"eighty":-1.86404,"marketCap":240288372},{"date":"2025-08-15","current":-2.26542,"twenty":-6.156275,"median":-3.900612,"eighty":-1.87168,"marketCap":258647483},{"date":"2025-08-22","current":-2.26069,"twenty":-6.144305,"median":-3.890098,"eighty":-1.890778,"marketCap":258107509},{"date":"2025-08-29","current":-2.251231,"twenty":-6.128418,"median":-3.827824,"eighty":-1.92165,"marketCap":257027562},{"date":"2025-09-05","current":-2.35055,"twenty":-6.121976,"median":-3.799992,"eighty":-1.925602,"marketCap":268367013},{"date":"2025-09-12","current":-2.449869,"twenty":-6.107404,"median":-3.74219,"eighty":-1.93461,"marketCap":279706464},{"date":"2025-09-19","current":-2.582295,"twenty":-6.103535,"median":-3.677964,"eighty":-1.952307,"marketCap":294825733},{"date":"2025-09-26","current":-3.07416,"twenty":-6.103378,"median":-3.543091,"eighty":-1.960886,"marketCap":350983015},{"date":"2025-10-03","current":-3.16875,"twenty":-6.084882,"median":-3.508838,"eighty":-1.966064,"marketCap":361782492},{"date":"2025-10-10","current":-3.878171,"twenty":-6.074043,"median":-3.510979,"eighty":-1.967068,"marketCap":442778573},{"date":"2025-10-17","current":-4.147751,"twenty":-6.062913,"median":-3.59126,"eighty":-1.975097,"marketCap":473557083},{"date":"2025-10-24","current":-4.256529,"twenty":-6.041368,"median":-3.707936,"eighty":-1.980826,"marketCap":485976483},{"date":"2025-10-31","current":-5.750439,"twenty":-6.046619,"median":-3.744331,"eighty":-1.985047,"marketCap":656539109},{"date":"2025-11-07","current":-5.854784,"twenty":-6.046619,"median":-3.79777,"eighty":-1.986886,"marketCap":614553293},{"date":"2025-11-14","current":-6.25113,"twenty":-6.074043,"median":-3.827824,"eighty":-1.989502,"marketCap":656156069},{"date":"2025-11-21","current":-6.195502,"twenty":-6.104132,"median":-3.878171,"eighty":-2.002315,"marketCap":650317083},{"date":"2025-11-28","current":-6.856078,"twenty":-6.134773,"median":-3.890098,"eighty":-2.017382,"marketCap":719655044},{"date":"2025-12-05","current":-6.320664,"twenty":-6.150597,"median":-3.89885,"eighty":-2.031318,"marketCap":663454802},{"date":"2025-12-12","current":-6.814357,"twenty":-6.187864,"median":-3.917739,"eighty":-2.03527,"marketCap":715275804},{"date":"2025-12-19","current":-6.925612,"twenty":-6.202522,"median":-4.030982,"eighty":-2.038234,"marketCap":726953776},{"date":"2025-12-26","current":-7.342817,"twenty":-6.232879,"median":-4.056541,"eighty":-2.044162,"marketCap":770746173},{"date":"2026-01-02","current":-6.904752,"twenty":-6.267809,"median":-4.06981,"eighty":-2.050547,"marketCap":724764157},{"date":"2026-01-09","current":-6.584894,"twenty":-6.292758,"median":-4.093288,"eighty":-2.054882,"marketCap":691189986},{"date":"2026-01-16","current":-5.215069,"twenty":-6.292758,"median":-4.112303,"eighty":-2.065989,"marketCap":547404952},{"date":"2026-01-23","current":-5.340231,"twenty":-6.291928,"median":-4.144069,"eighty":-2.070307,"marketCap":560542671},{"date":"2026-01-30","current":-5.263743,"twenty":-6.288275,"median":-4.176128,"eighty":-2.074127,"marketCap":552514065},{"date":"2026-02-06","current":-4.79091,"twenty":-6.285897,"median":-4.204325,"eighty":-2.07973,"marketCap":502882683},{"date":"2026-02-13","current":-4.568401,"twenty":-6.271979,"median":-4.22602,"eighty":-2.08467,"marketCap":479526738},{"date":"2026-02-20","current":-4.359798,"twenty":-6.2553,"median":-4.256529,"eighty":-2.093982,"marketCap":457630540},{"date":"2026-02-27","current":-4.797864,"twenty":-6.249281,"median":-4.259754,"eighty":-2.101306,"marketCap":503612556},{"date":"2026-03-06","current":-4.700516,"twenty":-6.238621,"median":-4.26556,"eighty":-2.104054,"marketCap":493394330},{"date":"2026-03-13","current":-4.610121,"twenty":-6.229687,"median":-4.302155,"eighty":-2.104429,"marketCap":483905978},{"date":"2026-03-20","current":-4.026033,"twenty":-6.20894,"median":-4.311653,"eighty":-2.110959,"marketCap":422596623},{"date":"2026-03-27","current":-3.928685,"twenty":-6.202926,"median":-4.267198,"eighty":-2.118489,"marketCap":412378397},{"date":"2026-04-02","current":-4.202375,"twenty":-6.202522,"median":-4.26169,"eighty":-2.124573,"marketCap":420073647},{"date":"2026-04-10","current":-4.765657,"twenty":-6.20108,"median":-4.26556,"eighty":-2.129912,"marketCap":476379815},{"date":"2026-04-17","current":-4.876831,"twenty":-6.198928,"median":-4.284574,"eighty":-2.138298,"marketCap":487492874},{"date":"2026-04-24","current":-4.45437,"twenty":-6.196543,"median":-4.359798,"eighty":-2.158925,"marketCap":445263248},{"date":"2026-05-01","current":-4.220904,"twenty":-6.187864,"median":-4.308896,"eighty":-2.183857,"marketCap":421925823},{"date":"2026-05-08","current":-4.313549,"twenty":-6.179795,"median":-4.311653,"eighty":-2.193349,"marketCap":431186706},{"date":"2026-05-15","current":-4.935589,"twenty":-6.170782,"median":-4.347791,"eighty":-2.193349,"marketCap":431868987},{"date":"2026-05-22","current":-4.693297,"twenty":-6.160203,"median":-4.359798,"eighty":-2.196313,"marketCap":410668145},{"date":"2026-05-29","current":-4.55869,"twenty":-6.152489,"median":-4.365307,"eighty":-2.198289,"marketCap":398889900},{"date":"2026-06-05","current":-4.289476,"twenty":-6.145809,"median":-4.360188,"eighty":-2.198289,"marketCap":375333410},{"date":"2026-06-12","current":-3.768995,"twenty":-6.13795,"median":-4.316397,"eighty":-2.200548,"marketCap":329790862},{"date":"2026-06-18","current":-4.468952,"twenty":-6.126808,"median":-4.313549,"eighty":-2.203948,"marketCap":391037737},{"date":"2026-06-26","current":-4.217685,"twenty":-6.117126,"median":-4.326091,"eighty":-2.204832,"marketCap":369051679},{"date":"2026-07-02","current":-3.99334,"twenty":-6.104164,"median":-4.314973,"eighty":-2.208169,"marketCap":349421271},{"date":"2026-07-10","current":-4.531768,"twenty":-6.104124,"median":-4.313549,"eighty":-2.214681,"marketCap":396534251},{"date":"2026-07-17","current":-4.092052,"twenty":-6.103378,"median":-4.308896,"eighty":-2.219277,"marketCap":358058651},{"date":"2026-07-24","current":-4.226659,"twenty":-6.103378,"median":-4.298726,"eighty":-2.232313,"marketCap":369836896},{"date":"2026-07-31","current":-3.903602,"twenty":-6.084882,"median":-4.292656,"eighty":-2.232313,"marketCap":341569107},{"date":"2026-08-07","current":-4.083078,"twenty":-6.074043,"median":-4.276491,"eighty":-2.23671,"marketCap":357273434},{"date":"2026-08-14","current":-4.663158,"twenty":-6.062913,"median":-4.289476,"eighty":-2.241319,"marketCap":406930442},{"date":"2026-08-21","current":-4.757173,"twenty":-6.046619,"median":-4.295552,"eighty":-2.242638,"marketCap":415134685}],"updateTime":1787460635279},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LXEO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658997430","title":"Lexeo Therapeutics Releases Corporate Presentation Outlining Cardiac Gene Therapy Pipeline, AAVrh.10 Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997430","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997430?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:29","pubTimestamp":1786534172,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics releases corporate presentation outlining cardiac gene therapy pipeline, AAVrh.10 platformLexeo highlighted a cardiac gene therapy platform built on its AAVrh.10 capsid, citing 27 p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLN41l9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971100","title":"Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971100","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971100?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:08","pubTimestamp":1786532889,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 50 percent increase over losses of $(0.60) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61137025/lexeo-therapeutics-q2-eps-0-30-misses-0-28-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971523","title":"Lexeo Net Loss Narrows to $25.9 Million in Q2 FY26; R&D Expenses Rise to $19 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971523","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971523?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:01","pubTimestamp":1786532495,"startTime":"0","endTime":"0","summary":"Lexeo net loss narrows to $25.9 million in Q2 FY26; R&D expenses rise to $19 millionLexeo reported a Q2 2026 net loss of USD 25.9 million, narrowing from a USD 26.1 million loss a year earlier.Loss pe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL6n6GJx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971166","title":"Press Release: Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971166?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532400,"startTime":"0","endTime":"0","summary":"statistical analysis plan  for LX2006 under the accelerated approval. -- SUNRISE-FA 2: The study was initiated in June with activation of. the first trial site and enrollment of the first patient. Site. activation efforts are ongoing to support continued enrollment in. advance across multiple sites in the US and globally. Patients. enrolled in CLARITY-FA are eligible to participate in SUNRISE-FA. 2, supporting continued enrollment into the pivotal study once. -- In June 2026, Lexeo announced publication of LX2006 data in the Journal. LX2006 is generally well tolerated, with signs of efficacy in Phase I/II","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SAP","BK4535","BK4539","BK4528","BK4130","BK4023","BK4588","FA","LXEO","BK4613","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545220","title":"Lexeo Therapeutics, - Lx2020 Holds Rmat, Orphan Drug, and Fast Track Designations from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657545220?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:00","pubTimestamp":1785927602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA9NQGPK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657452795","title":"Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Lx2020 for the Treatment of Pkp2 Arrhythmogenic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2657452795","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657452795?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:00","pubTimestamp":1785927602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA9NQGPK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648523666","title":"Have Insiders Sold Lexeo Therapeutics Shares Recently?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648523666","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648523666?lang=en_us&edition=fundamental","pubTime":"2026-07-03 19:12","pubTimestamp":1783077152,"startTime":"0","endTime":"0","summary":"We note that the Lexeo Therapeutics, Inc. ( NASDAQ:LXEO ) Chief Medical Officer, Narinder Bhalla, recently sold US$99k...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/news/have-insiders-sold-lexeo-therapeutics-shares-recently","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/news/have-insiders-sold-lexeo-therapeutics-shares-recently","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LXEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648573603","title":"Top Brass at Lexeo Therapeutics Quietly Unload a Chunk of Company Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2648573603","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648573603?lang=en_us&edition=fundamental","pubTime":"2026-07-02 10:02","pubTimestamp":1782957761,"startTime":"0","endTime":"0","summary":"New insider activity at Lexeo Therapeutics, Inc. ( ($LXEO) ) has taken place on July 1, 2026. Lexeo Therapeutics, Inc. has seen notable insider sel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-brass-at-lexeo-therapeutics-quietly-unload-a-chunk-of-company-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-brass-at-lexeo-therapeutics-quietly-unload-a-chunk-of-company-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647302003","title":"Lexeo Therapeutics Holds Virtual Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2647302003","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647302003?lang=en_us&edition=fundamental","pubTime":"2026-06-30 05:06","pubTimestamp":1782767215,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics holds virtual annual stockholder meetingLexeo Therapeutics held its 2026 annual stockholder meeting on June 25, 2026, conducted virtually.Stockholders selected three Class III direc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL8mhVvR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646801921","title":"Lexeo Therapeutics is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2646801921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646801921?lang=en_us&edition=fundamental","pubTime":"2026-06-25 23:00","pubTimestamp":1782399600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings(END) Dow Jones NewswiresJune 25, 2026 11:00 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646877610","title":"Lexeo Therapeutics price target lowered to $9 from $12 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2646877610","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646877610?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:35","pubTimestamp":1782387345,"startTime":"0","endTime":"0","summary":"JPMorgan lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $9 from $12 and keeps an Overweight rating on the shares. The firm updated...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-9-from-12-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-9-from-12-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644729996","title":"Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2644729996","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644729996?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:01","pubTimestamp":1781726460,"startTime":"0","endTime":"0","summary":"Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313795/0/en/Lexeo-Therapeutics-Announces-Publication-in-JAMA-Cardiology-of-Phase-I-II-Data-for-LX2006-in-Friedreich-Ataxia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFT","BK4130","BK4139","BK4110","BK4535","FA","BK4539","LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643019200","title":"BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex","url":"https://stock-news.laohu8.com/highlight/detail?id=2643019200","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643019200?lang=en_us&edition=fundamental","pubTime":"2026-06-16 02:13","pubTimestamp":1781547236,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Terawulf, PaychexWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nL6N42N0W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRIP","PTCT","LXEO","ELTX","NMRA","DDOG","PSKY","CONY","ABNY","TRAW","CMTL","RCL","SCCO","DAL","MRAL","FISV","SNK","NEM","SPCU","NCLH","RIOT","MU","CONI","LUV","ICOI","XOMX","SHAZ","CCL","COYY","MARA","FOXA","BAND","COIW","ABNB","AAL","MUU","LCLN","XOM","APA","COII","FCX","COIN","PTRN","OXY","SPCX","UAL","XOMO","HUT","CVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643060712","title":"Lexeo Therapeutics Finalizes Study Design for Friedreich Ataxia Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2643060712","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643060712?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:29","pubTimestamp":1781530192,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics  has finalized a pivotal study design to evaluate gene therapy candidate LX2006 in Friedreich ataxia cardiomyopathy, the company said Monday.The trial protocol and statistical analysis plan are intended to provide clinical evidence to support the submission of a biologics license application to the US Food and Drug Administration for the therapy under the accelerated approval pathway in 2028, according to a statement.Lexeo said it remains in ongoing discussions with the agency regarding the confirmatory evidence strategy for the study.The company added that it expects a topline data readout in H2 of 2027 and a biologics license application submission under the accelerated approval pathway in H1 of 2028.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643208604","title":"Lexeo finalizes SUNRISE-FA 2 pivotal trial protocol, statistical analysis plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2643208604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643208604?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:35","pubTimestamp":1781523308,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (LXEO) announced that the company has finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan intended t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-finalizes-sunrise-fa-2-pivotal-trial-protocol-statistical-analysis-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-finalizes-sunrise-fa-2-pivotal-trial-protocol-statistical-analysis-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FA","BK4130","LXEO","BK4139","BK4535","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643270235","title":"Lexeo Therapeutics releases corporate presentation on cardiac gene therapy platform for inherited heart disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2643270235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643270235?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:15","pubTimestamp":1781522125,"startTime":"0","endTime":"0","summary":"Lexeo outlined a cardiac gene therapy strategy built around its AAVrh10 capsid, citing ~1.5x to 2x higher heart biodistribution than AAV9.LX2006 in Friedreich ataxia cardiomyopathy targets pivotal study initiation in Q2 2026, topline data in 2H 2027, potential BLA in 1H 2028.SUNRISE-FA 2 planned as open-label with untreated control; 26 participants; primary endpoint LVMI by cardiac MRI at 6 months; dose 1.2x10^12 vg/kg.Phase I/II LX2006 update showed 18% mean LVMI reduction at 6 months in patients with abnormal baseline LVMI; 28% in higher-dose cohorts.LX2020 in PKP2 arrhythmogenic cardiomyopathy guided to a 12-month high-dose data update in Q4 2026, with regulatory engagement expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLbgncsH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643514270","title":"Lexeo finalizes SUNRISE-FA 2 pivotal trial design for LX2006 in Friedreich ataxia cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2643514270","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643514270?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:01","pubTimestamp":1781521298,"startTime":"0","endTime":"0","summary":"Lexeo finalized the pivotal SUNRISE-FA 2 trial design for LX2006 in Friedreich ataxia cardiomyopathy, targeting accelerated-approval filing in 2028.Results have not been presented; a topline efficacy readout is expected in the second half of 2027, with first dosing slated by end of June.The study will compare a one-time gene therapy infusion against a concurrent untreated control, aiming to show improvement in heart disease progression.Enrollment is limited to patients with abnormal heart muscle measurements at baseline, sharpening focus on those most likely to benefit.Manufacturing readiness is positioned to support BLA timing, with commercial-scale product already available for dosing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL1QL18y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","LU2210150020.SGD","LU0314104364.USD","SG9999014021.USD","NDAQ","LU2095319765.USD","SG9999014039.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","BK4588","BK4139","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643636270","title":"Lexeo Therapeutics - Topline Data Readout Expected in H2 2027; Bla Submission in H1 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2643636270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643636270?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:00","pubTimestamp":1781521200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA2MRKGS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643270638","title":"Lexeo Therapeutics - Sunrise-Fa 2 Initiation on Track for Q2 2026; First Patient Expected by End of June","url":"https://stock-news.laohu8.com/highlight/detail?id=2643270638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643270638?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:00","pubTimestamp":1781521200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA2MRKGS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643270314","title":"Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for Lx2006 Gene Therapy in Friedreich Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2643270314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643270314?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:00","pubTimestamp":1781521200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA2MRKGS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}